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ABSTRACT
Numerous surveillance studies confirm that methicillin resistance is common among isolates of
Staphylococcus aureus, with resistance rates as high as 50%. Long associated with nosocomial infections,
methicillin-resistant S. aureus (MRSA) is now emerging as a community-based pathogen. Studies
indicate that infections with MRSA are associated with greater morbidity and mortality than similar
infections with methicillin-sensitive strains. The spread of MRSA has contributed to an increasing
reliance on vancomycin to treat infections caused by this pathogen. However, with isolates of S. aureus
becoming increasingly resistant to multiple antibiotic agents, new antimicrobial therapies are urgently
required. Daptomycin, the first in a novel class of antibiotics called the cyclic lipopeptides, was
approved in the USA in 2003 for the treatment of complicated skin and soft tissue infections (cSSTIs)
caused by Gram-positive bacteria. Post-marketing experience in the USA has confirmed the clinical
efficacy of daptomycin for the treatment of cSSTIs observed in clinical trials. Studies have also shown
daptomycin to be as effective as current standard therapy for the treatment of S. aureus bacteraemia,
including those with known or suspected infective endocarditis. A supplemental new drug application
for daptomycin for treatment of S. aureus bacteraemia and right-sided infective endocarditis was
approved in May 2006 by the US FDA. The availability of daptomycin has improved treatment options
for infections caused by Gram-positive pathogens.
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INTRODUCTION
Since the introduction of antimicrobials, bacteria
have developed mechanisms for resisting the
effects of antibiotics. The evolution and spread
of bacterial species with increasing antimicrobial
resistance stems from several factors, including
widespread and inappropriate use of antibiotics,
extensive use of these agents as growth enhancers
in animal feed, and the increase in regional and
international travel [1–3]. The emergence of
multidrug resistance in Gram-positive bacteria
(pneumococci, enterococci and staphylococci) is a
particularly important development.
Perhaps the pathogen of greatest concern is
Staphylococcus aureus, because of its intrinsic
virulence, its ability to cause an array of life-
threatening conditions, and its capacity to adapt
to different environmental conditions [4]. S. aureus
is now the leading cause of nosocomial infections
and is becoming an increasing concern in the
community setting [5,6]. Methicillin-resistant
strains of S. aureus, first reported in the early
1960s, are now endemic around the world; resist-
ance rates of 50% or more have been reported
across the USA, some parts of Europe and in the
Far East [5,7,8]. Isolates of S. aureus from across
the USA and other countries are increasingly
resistant to multiple antimicrobial agents [5],
resulting in fewer effective antibiotics to treat
infections caused by this pathogen. Reports of
S. aureus isolates with intermediate or complete
resistance to vancomycin, although limited, high-
light the need for new antibiotic therapies [9,10].
This article provides a US perspective on the
problem of resistance in S. aureus and the emer-
gence of resistant strains in community settings. It
Corresponding author and reprint requests: A. W. Karchmer,
Division of Infectious Diseases, Lowry Medical Office Build-
ing, Suite GB, Beth Israel Deaconess Medical Center, 330
Brookline Avenue, Boston, MA 02215, USA
E-mail: akarchme@bidmc.harvard.edu
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
will also examine the utility of existing and
emerging antibiotics for the treatment of infec-
tions caused by this important pathogen.
METHICILLIN RESISTANCE IN
S . AUREUS IN THE USA: DATA FROM
SURVEILLANCE STUDIES
Numerous surveillance studies confirm that
methicillin resistance is common among S. aureus
isolates in the USA, in both hospital and com-
munity-onset infections (Table 1). The National
Nosocomial Infections Surveillance (NNIS) Sys-
tem collects data from more than 300 hospitals
that provide general medical ⁄ surgical inpatient
services to adults or children requiring acute
care. The most recent data from the NNIS system
reveal that the proportion of methicillin-resistant
S. aureus (MRSA) is continuing to rise; in
patients with nosocomial infections in intensive
care units, resistance rates reached almost 60%
by the end of 2003 [6]. This represents an
increase of 11% compared with the mean rate
of resistance during 1998–2002. The SENTRY
Antimicrobial Surveillance Program tracks resist-
ance trends and the spectrum of microbial
pathogens on a global scale [5]. This programme
differs from other surveillance projects in that it
monitors both nosocomial and community-onset
infections, with identification and susceptibility
testing being performed at a central laboratory
rather than at participating centres. The SENTRY
study reported a steady increase in methicillin
resistance among nosocomial and community
S. aureus isolates in the 3-year period between 1
January 1997 and 31 December 1999 [5]. For
nosocomial strains, the rate of methicillin resist-
ance increased from 34% to 45%, while for
community-onset strains, it increased from 22%
to 28%. These surveillance programmes provide
an excellent overview of rates of antimicrobial
resistance, but large teaching hospitals are often
over-represented. As a result, fewer data exist
from smaller and ⁄ or non-teaching hospitals. A
large, representative survey of US hospitals,
stratified by the number of beds, geographical
region and teaching status, assessed antimicro-
bial resistance rates associated with four import-
ant microbial pathogens, including MRSA [11].
This study found that the frequency of MRSA
increased as the number of beds increased, and
was higher in teaching hospitals than in non-
teaching hospitals. Overall, the study confirmed
that the frequency of MRSA is high in hospitals
of all types.
COMMUNITY-ASSOCIATED MRSA
Infections due to MRSA that originate in the
community are an emerging problem in many
parts of the world. Several outbreaks of commu-
nity-associated MRSA (CA-MRSA) have been
reported in the USA in recent years among
inmates of correctional facilities, professional
football players, men who have sex with men,
military recruits and children in day care centres
[12–15]. The populations affected by these out-
breaks lacked established risk-factors for acquir-
ing MRSA, indicating that MRSA has successfully
evolved and transformed into a community-asso-
ciated pathogen [16].
CA-MRSA strains differ from healthcare-asso-
ciated MRSA in several important ways [17].
These include a unique genetic element that
mediates methicillin resistance (the staphylo-
coccal cassette chromosome mec type IV), resis-
tance to fewer antimicrobial drugs, and the
presence of genes that mediate specific virulence
factors. CA-MRSA strains typically carry the
Panton–Valentine leukocidin genes, which pro-
duce cytotoxins that cause tissue necrosis and
leukocyte destruction and are associated with
staphylococci causing skin infections and necro-
Table 1. Methicillin resistance rates among Staphylococcus







Diekema et al. 2004a [11] 494 1999–2001 36




ICAREb [45] 41 1996–1997 33
NNISc [6] 315 2003 59.5
SCOPEd [46] 49 1995–1998 29
ICARE, Intensive Care Antimicrobial Resistance Epidemi-
ology; NNIS, National Nosocomial Infections Surveillance;
SCOPE, Surveillance and Control of Pathogens of Epi-
demiologic Importance.
aNosocomial and community isolates included.
bIsolates from intensive care units and general wards.
cNosocomial intensive care unit isolates only.
dNosocomial bloodstream isolates only.
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tising pneumonia [18]. In addition, these strains
often carry genes mediating several exotoxins that
can function as superantigens eliciting exagger-
ated inflammatory responses [19]. A particular
concern with CA-MRSA is its association with
syndromes that were not typically caused by
staphylococci, including necrotising fasciitis,
Waterhouse–Friderichsen syndrome and fatal
necrotising pneumonia [20–22].
The current distinction between CA-MRSA and
healthcare-associated MRSA would be anticipa-
ted to blur if CA-MRSA begins to be transmitted
in healthcare settings [23]. Several recent studies
highlight the emergence of CA-MRSA as a
nosocomial pathogen and a major cause of
clinically relevant infections. A study in Atlanta,
Georgia identified a high prevalence (>7%) of
colonisation with MRSA among patients admitted
to an urban public hospital [24]. Colonisation was
determined on the basis of anterior nares cultures
obtained within 48 h of admission. Molecular
typing demonstrated that a significant number of
patients (2.2% of all adults admitted to the
hospital) were colonised with isolates belonging
to the USA300 CA-MRSA genotype. A study at
the same institution has identified CA-MRSA as a
significant cause of healthcare-associated and
nosocomial bloodstream infections [25]. Con-
secutive MRSA isolates recovered from patients
with bloodstream infections were subjected to
molecular typing studies. Of the 116 isolates
available for genotyping, 34% were of the
USA300 genotype, the predominant cause of
CA-MRSA infections in this part of the USA. Of
49 episodes of nosocomial bacteraemia, ten were
caused by USA300 organisms. The study also
identified injection drug use and skin and soft
tissue infections (SSTIs) as important risk-factors
for isolation of the USA300 genotype [25].
Another study evaluated MRSA infections
identified from population-based surveillance in
Baltimore and Atlanta and from hospital labor-
atory-based sentinel surveillance of 12 hospitals
in Minnesota [26]. From 2001 to 2002, 2107 of
13 253 (16%) isolates were confirmed or prob-
able CA-MRSA. The percentage of CA-MRSA in
the study areas ranged from 8% to 20%. Of
these 2107 isolates, 1647 (78%) were associated
with clinical illness that required treatment. The
most common infections involved skin and soft
tissues, although 6% of infections were consid-
ered invasive. Attributable mortality was low,
but 23% of patients were hospitalised specific-
ally for MRSA disease.
MRSA IS ASSOCIATED WITH
POORER PATIENT OUTCOMES
COMPARED WITH METHICILIN-
SUSCEPTIBLE S . AUREUS
Infections with antibiotic-resistant organisms are
thought tobeassociatedwithgreatermorbidity and
mortality than similar infections with antibiotic-
susceptible strains [27]. Numerous studies have
investigated the differences in mortality among
patients with methicillin-susceptible S. aureus
(MSSA) bacteraemia and MRSA bacteraemia, with
conflicting results [28]. A meta-analysis of 31
studies examined the impact of methicillin resist-
ance onmortality in S. aureus bacteraemia [28]. The
31 studies included a total of 3963 patients with
S. aureus bacteraemia; 2603 patients had MSSA
bacteraemia and 1360 had MRSA bacteraemia,
primarily due to healthcare-associated strains. On
combining results from all studies, MRSA bacter-
aemia was associated with an increase in mortality
compared with MSSA bacteraemia (pooled
OR 1.93; 95% CI 1.54–2.42). The overall difference
was statistically significant (p <0.001), although
there was significant heterogeneity among the
results of the individual studies (p 0.03). Thepooled
OR for mortality associated with MRSA bacterae-
mia in the 11 studies that adjusted for potential
confounding variables was 1.88 (95% CI 1.33–2.69;
p <0.001), with no significant heterogeneity among
the results of the studies (p 0.36).
Several potential explanations have been pro-
posed for the apparent increase in mortality with
MRSA infections compared with MSSA infec-
tions, including enhanced virulence of MRSA,
decreased effectiveness of vancomycin vs. semi-
synthetic penicillins and delay in appropriate
antibiotic therapy [28]. There is little evidence to
suggest that MRSA strains are more virulent than
MSSA strains [28], although CA-MRSA strains
may have increased virulence potential compared
with healthcare-associated MRSA strains [29,30].
The emergence of methicillin resistance has con-
tributed to reliance on vancomycin, with the
assumption that it is as effective as b-lactam
antibiotics. However, data from several studies
suggest that this assumption may not be justified
[31–33]. A prospective, observational study of
patients with S. aureus bacteraemia assessed the
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impact of antibiotic treatment with nafcillin or
vancomycin [31]. Among patients with MSSA
bacteraemia, nafcillin treatment was associated
with a shorter duration of infection, fewer cases of
relapse and fewer cases of bacteriological failure
(persistent bacteraemia or relapse) (Fig. 1). Other
studies have demonstrated that delaying effective
therapy for S. aureus bacteraemia is associated
with poorer patient outcomes [34–36]. A retro-
spective cohort analysis of 167 episodes of
S. aureus bacteraemia evaluated the effect of
delayed treatment on clinical outcomes [35].
Classification and regression tree analysis was
used to select the time-interval (44.75 h) that
served as the breakpoint between early and
delayed treatment, with patients stratified accord-
ingly. On logistic regression analysis, MRSA was
found to be the most significant predictor of
delayed treatment (OR 8.3; 95% CI 2.6–16.8). De-
layed treatment was associated with a 1.7-fold
increase in the infection-related mortality rate
compared with early treatment (33% vs. 19%,
p 0.05). Following adjustment for clinical charac-
teristics associated with infection-related mortal-
ity (APACHE II score, high-risk infection source,
receipt of mechanical ventilation, presence of
decubitus ulcers), delayed treatment remained
an independent predictor of mortality (OR 3.8;
95% CI 1.3–11.0; p 0.01). The influence of delayed
treatment on mortality was most evident in
critically ill patients, particularly those with an
APACHE II score of ‡15.5 and a high-risk source
of infection. Delayed treatment was also associ-
ated with an increased length of hospital stay
after onset of S. aureus bacteraemia.
Recently, infections caused by MRSA with
reduced susceptibility to vancomycin have
emerged [37]. Strains characterised as having
intermediate-level resistance to vancomycin [van-
comycin-intermediate S. aureus (VISA); MIC 8–
16 mg ⁄L] and vancomycin-resistant strains
(VRSA; MIC ‡32 mg ⁄L, due to the vanA deter-
minant that mediates resistance to vancomycin in
enterococci) are relatively rare. However, hetero-
geneous VISA (hVISA) strains are being recog-
nised more frequently. These strains appear to be
susceptible on routine MIC determinations
(MIC 1–4 mg ⁄L), but possess low-number sub-
populations of vancomycin-intermediate cells.
Under selective pressure, these strains can exhibit
overt intermediate resistance to vancomycin and
cause persistent infection in the face of appropri-
ately dosed vancomycin (i.e., lead to vancomycin
therapy failure) [38–40]. While hVISA was not
recognised as a cause of increased mortality in
earlier studies, this phenomenon could have
played a role in recent reports of vancomycin
failure [40].
DAPTOMYCIN: A NEW TREATMENT
OPTION FOR INFECTIONS CAUSED
BY GRAM-POSITIVE PATHOGENS
Daptomycin, the first in a novel class of antibiotics
called the cyclic lipopeptides, was approved in
the USA in 2003 for the treatment of complicated
SSTIs (cSSTIs) caused by Gram-positive bacteria.
A supplemental new drug application for dapto-
mycin, for treatment of S. aureus bacteraemia and
right-sided infective endocarditis caused by either
MSSA or MRSA, was approved in May 2006 by
the US FDA. Several issues are beginning to drive
the use of daptomycin in the USA. These include
increasing resistance to other antibiotics among
Gram-positive pathogens, the limited efficacy of
vancomycin against MRSA, and the emergence of
MRSA with reduced susceptibility to vancomy-
cin. These hVISA strains are difficult to detect
with methods commonly used for susceptibility
testing, but have been associated with vancomy-
cin treatment failure. In one example, a 47-year-
old African-American male presenting with
MRSA endocarditis relapsed after receiving
appropriately dosed vancomycin for 6 weeks
[41]. Several lines of evidence indicate that this
treatment failure occurred because the patient
was infected with a strain of hVISA that, under
vancomycin selective pressure, emerged as a
slightly more resistant variant that caused the
Fig. 1. Failure of vancomycin vs. nafcillin in the treatment
of methicillin-susceptible Staphylococcus aureus bacteraemia
[31]. Reproduced with permission from Lippincott Wil-
liams & Wilkins.
18 Clinical Microbiology and Infection, Volume 12 Supplement 8, 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12 (Suppl. 8), 15–21
infection to relapse. When studied in a rabbit
model of endocarditis, the relapse strain failed to
respond to therapeutic doses of vancomycin that
eradicated the initial strain from aortic valve
vegetations. In addition, the two strains were
genotypically strongly related, indicating that this
was a true relapse rather than a re-infection.
Two pivotal, randomised, evaluator-blinded
studies have shown daptomycin to be effective
for the treatment of cSSTIs caused by Gram-
positive bacteria [42]. In these studies, which
involved more than 1000 patients, the safety and
efficacy of daptomycin (4 mg ⁄ kg once-daily) were
comparable to those of vancomycin or penicillin-
ase-resistant penicillins. The clinical efficacy of
daptomycin for the treatment of Gram-positive
cSSTIs in clinical trials has been confirmed by post-
marketing experience in the USA. A retrospective,
observational chart review assessed the clinical
outcome of 1160 patients receiving daptomycin,
557 of whom had SSTIs (R. Owens et al. ICAAC
2005). The pathogens isolated most frequently
were S. aureus (74%) and Enterococcus spp. (19%),
and the mean daily dose of daptomycin was
4.4 mg ⁄kg. In patients with cSSTIs (n ¼ 344), rates
of cure, improvement and failure were 53%, 43%
and 4%, respectively (Fig. 2). These post-market-
ing data also indicate no differences in outcomes
according to the type of cSSTI, which included
wound infections, major abscesses, surgical site
infections, diabetic and non-diabetic ulcers and
necrotising infections.
Data from the same post-marketing registry
show that daptomycin has been used successfully
‘off-label’ to treat other infections, including
endocarditis (left- and right-sided), osteomyelitis,
orthopaedic infections and bacteraemia (catheter-
and non-catheter-related (S. Antony et al. IDSA
2005; Y. Golan et al. IDSA 2005; K. Lamp et al.
IDSA 2005; D. Levine and K. Lamp, IDSA 2005;
G. Sakoulas et al. IDSA 2005).
The efficacy of daptomycin for the treatment of
S. aureus bacteraemia and known or suspected
infective endocarditis has also been assessed in a
randomised, open-label phase III study [43].
Daptomycin (6 mg ⁄ kg once-daily) was compared
with standard therapy (vancomycin or semi-
synthetic penicillin, each with initial synergistic
gentamicin). A blinded independent adjudication
committee assessed treatment outcomes at the
end of therapy and test of cure (TOC) follow-up
(42 days after end of therapy). The primary
efficacy endpoints were treatment success at
TOC in the modified intention-to-treat and per-
protocol populations. In the modified intention-
to-treat analysis of 235 patients, success rates at
TOC were 44.2% in the daptomycin group and
41.7% in the comparator group (2.4% difference;
95% CI )10.2–15.1) (Fig. 3). In the per-protocol
analysis (n ¼ 79), TOC success rates were 54.4%
and 53.3% in the daptomycin and comparator
groups, respectively (1.1% difference;
95% CI )15.6–17.8). Success rates with daptomy-
cin for MRSA and MSSA in the modified inten-
tion-to-treat population were 44.4% and 44.6%,
respectively; with comparator treatment, the suc-
cess rates were 31.8% for MRSA and 48.6% for
MSSA. Success rates were also similar in the two
treatment groups when patients were grouped
according to diagnosis at entry into the study.
Reported rates of adverse events, serious adverse
events and drug-related adverse events were
generally similar in the daptomycin and compa-
rator groups. Elevations in creatine phosphokin-
ase were seen in 25% of daptomycin-treated
patients and in 12.5% of comparator-treated
Fig. 2. Daptomycin treatment outcome in 344 patients
with complicated skin and soft tissue infections (R. Owens
et al. ICAAC 2005)
Fig. 3. Treatment success rates for daptomycin and com-
parator antibiotics in patients with Staphylococcus aureus
bacteraemia and known or suspected infective endocardi-
tis [43].
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patients (p 0.038). Declining renal function was
reported in 19.8% of patients treated with dapto-
mycin and in 46.8% of patients receiving compa-
rator drugs (p <0.001).
SUMMARY
Surveillance studies indicate that resistance to
b-lactam antibiotics among S. aureus continues to
increase. In fact, MRSA has become endemic in
the USA and around the world. MRSA was once
restricted to healthcare institutions; mounting
evidence indicates that it is now emerging as a
community-based pathogen. This emergence of
CA-MRSA as a significant cause of staphylococcal
infections presents new particularly morbid syn-
dromes as well as challenges for reducing no-
socomial transmission of MRSA. The increasing
prevalence of MRSA has contributed to a reliance
on vancomycin to treat infections caused by this
pathogen. However, the efficacy of vancomycin
against MRSA is suboptimal, and strains of MRSA
with reduced vancomycin susceptibility are
increasingly being recognised. Daptomycin is a
new antimicrobial agent that is effective and
approved for the treatment of cSSTIs caused by
Gram-positive bacteria. Studies also demonstrate
that daptomycin is not inferior to current stand-
ard therapy for the treatment of patients with
S. aureus bacteraemia, including those with
known or suspected infective endocarditis. The
availability of daptomycin has improved options
for the treatment of infections caused by Gram-
positive bacteria.
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